Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Sacituzumab govitecan-hziy

(Trodelvy®)

Trodelvy®

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 180 mg lyophilized powder in single-dose vials)
Drug ClassTrop-2-directed antibodies and topoisomerase inhibitor conjugates
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease
  • Indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
  • Indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
  • Metastatic Urothelial Carcinoma: Sacituzumab govitecan (Trodelvy) demonstrated an objective response rate (ORR) ranging from 27% to 52% as monotherapy, and 34% to 75% when combined with anti-PD-1 agents. It has shown efficacy similar to other antibody-drug conjugates (ADCs) like enfortumab vedotin, which is approved for first-line treatment in combination with pembrolizumab.
  • Metastatic Triple-Negative Breast Cancer (mTNBC): Sacituzumab govitecan outperformed other treatments in second and subsequent lines of treatment, including progression-free survival (PFS) and overall survival (OS) endpoints. It was superior to treatments like PARP (poly (ADP-ribose) polymerase) inhibitors (talazoparib, olaparib) and chemotherapy agents (nab-paclitaxel, capecitabine, eribulin) in ORR, PFS, and OS.
  • Guideline Recommendations: Sacituzumab govitecan is recommended as a third-line treatment for patients with mTNBC who have already undergone at least two prior therapies.
  • The studies indicate that antibody-drug conjugates (ADCs) like sacituzumab govitecan are designed to reduce systemic toxicities compared to conventional chemotherapy. However, specific adverse effects of sacituzumab govitecan are not provided.
  • In mTNBC, platinum-based polychemotherapies were noted to have higher toxicity compared to other treatments, but detailed safety outcomes for sacituzumab govitecan are not specified.
  • The population types and subgroups in the provided evidence focus on patients with metastatic urothelial carcinoma and mTNBC. Specific subgroups include those with programmed cell death ligand 1 (PD-L1)-positive vs. PD-L1-negative mTNBC, and patients with germline breast cancer gene (BRCA) mutations, where sacituzumab govitecan demonstrated superior outcomes in later treatment lines, especially in PD-L1-positive and germline BRCA mutation-positive mTNBC.